What is UNITY Global Registry Trial?
UNITY Global Registry Trial is a 12-week study that aims to collect information from healthcare workers (HCWs) who are exposed to SARS-CoV-2 through their work. The UNITY Global Registry Trial is an observational cohort study this means that there are no preventative interventions, no visits or laboratory tests are mandated.
The aim of this registry to produce real-world evidence to potentially inform recommendations and policies on COVID-19 prevention measures, including prophylactic use of potential drug therapies.
Who can join the study?
Healthcare workers at participating facilities in South Africa can take part in the study if they are exposed to patients with suspected or confirmed COVID-19 and therefore may catch the disease. All participants must meet the inclusion criteria.
1. Must 18 years or older
2. Healthcare workers working in a healthcare facility.
3. Should be exposed, through ongoing or recurrent contact to a clinically diagnosed COVID-19 patient within 30 days of enrolment.
4. Must have access to an internet-connected computer, smartphone, or tablet
5. Be willing to be contacted or reminded to enter data
6. Be willing to provide a secondary contact for follow-up, if needed
1. You will not be able to take part if you had COVID-19 or symptoms prior
to being exposed in your workplace.
If you meet the inclusion criteria and are interested in joining the study you will be asked to sign an online consent form.
This is a remote research trial conducted primarily by entering information into an online database. You will be asked to provide information about your health and your COVID-19 exposures at work when you join the study and then weekly for 12 weeks.
This study includes an optional blood test by fingerprick test to see if you have SARS-CoV-2 antibodies. Your blood test can only be tested if you agreed to it on the online consent form.
If you agree to take part, you will not be paid for your participation/involvement.
To learn more
For more on the UNITY Global Registry Trial please email email@example.com
Organisers and Funders
This study is implemented by Wits RHI at the University of the Witwatersrand. The trial is sponsored globally by Certara, Inc, with funding from the COVID-19 Therapeutic Accelerator. The principal investigators (PI) are not receiving any money or other payment for asking you to be part of the study. In South Africa, the Wits RHI has overall responsibility for the conduct of the study and are responsible for ensuring the study is carried out ethically and in the best interests of the study participants.
<p> Latest Update: 15 February 2021</p>